Background: Intrathecal baclofen (ITB) treatment is considered a powerful tool in the management of severe spasticity in neurological conditions such as multiple sclerosis, cerebral palsy, and traumatic spinal cord and brain injury. Objectives: The objective of this study was to assess the effectiveness of the ITB in patients with inherited ataxia suffering from severe painful spasms and/or spasticity. Method: A total of 5 patients with spinocerebellar ataxia 3 or 7 or Friedreich’s ataxia were included in this observational multicenter study. The patients were interviewed and completed outcome measures assessing pain (The Brief Pain Inventory), fatigue (Fatigue Severity Scale), and life satisfaction (LiSAT-9) before and 1 year after the treatment. Spasticity (Modified Ashworth Scale) and spasm frequency (SPFS) were measured objectively for each patient. Results: The mean treatment time was 1.9 years. Evaluation of established standard forms revealed symptomatic relief from spasticity, spasms, pain, and fatigue in addition to improved body posture, sleep, and life satisfaction after ITB treatment. Conclusions: We report the potential beneficial effects of ITB treatment in patients with inherited ataxia who also suffer from spasticity/spasms. ITB treatment indication in neurological disorders allows for extension to the treatment of spasticity/ spasms in patients with hereditary ataxia.

1.
Espinós
C
,
Palau
F
.
Genetics and pathogenesis of inherited ataxias and spastic paraplegias
.
Adv Exp Med Biol
.
2009
;
652
:
263
96
.
[PubMed]
0065-2598
2.
Parkinson
MH
,
Boesch
S
,
Nachbauer
W
,
Mariotti
C
,
Giunti
P
.
Clinical features of Friedreich’s ataxia: classical and atypical phenotypes
.
J Neurochem
.
2013
Aug
;
126
Suppl 1
:
103
17
.
[PubMed]
0022-3042
3.
Lebre
AS
,
Brice
A
.
Spinocerebellar ataxia 7 (SCA7)
.
Cytogenet Genome Res
.
2003
;
100
(
1-4
):
154
63
.
[PubMed]
1424-8581
4.
Albright
AL
.
Baclofen in the treatment of cerebral palsy
.
J Child Neurol
.
1996
Mar
;
11
(
2
):
77
83
.
[PubMed]
0883-0738
5.
Lapeyre
E
,
Kuks
JB
,
Meijler
WJ
.
Spasticity: revisiting the role and the individual value of several pharmacological treatments
.
NeuroRehabilitation
.
2010
;
27
(
2
):
193
200
.
[PubMed]
1878-6448
6.
Panourias
IG
,
Themistocleous
M
,
Sakas
DE
:
Intrathecal baclofen in current neuromodulatory practice: established indications and emerging applications.
Acta neurochirurgica Supplement
2007
;97:145-154.
7.
Albright
AL
,
Gilmartin
R
,
Swift
D
,
Krach
LE
,
Ivanhoe
CB
,
McLaughlin
JF
.
Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin
.
J Neurosurg
.
2003
Feb
;
98
(
2
):
291
5
.
[PubMed]
0022-3085
8.
Hasnat
MJ
,
Rice
JE
.
Intrathecal baclofen for treating spasticity in children with cerebral palsy
.
Cochrane Database Syst Rev
.
2015
Nov
;(
11
):
CD004552
.
[PubMed]
1469-493X
9.
McIntyre
A
,
Mays
R
,
Mehta
S
,
Janzen
S
,
Townson
A
,
Hsieh
J
, et al
Examining the effectiveness of intrathecal baclofen on spasticity in individuals with chronic spinal cord injury: a systematic review
.
J Spinal Cord Med
.
2014
Jan
;
37
(
1
):
11
8
.
[PubMed]
1079-0268
10.
Meythaler
JM
,
Guin-Renfroe
S
,
Brunner
RC
,
Hadley
MN
.
Intrathecal baclofen for spastic hypertonia from stroke
.
Stroke
.
2001
Sep
;
32
(
9
):
2099
109
.
[PubMed]
0039-2499
11.
Rémy-Néris
O
,
Tiffreau
V
,
Bouilland
S
,
Bussel
B
.
Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait
.
Arch Phys Med Rehabil
.
2003
May
;
84
(
5
):
643
50
.
[PubMed]
0003-9993
12.
Shakespeare
DT
,
Boggild
M
,
Young
C
.
Anti-spasticity agents for multiple sclerosis
.
Cochrane Database Syst Rev
.
2001
;(
4
):
CD001332
.
[PubMed]
1469-493X
13.
Stampacchia
G
,
Gerini
A
,
Mazzoleni
S
.
Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: long term follow-up
.
NeuroRehabilitation
.
2016
Apr
;
38
(
4
):
385
93
.
[PubMed]
1053-8135
14.
Ben Smail
D
,
Jacq
C
,
Denys
P
,
Bussel
B
.
Intrathecal baclofen in the treatment of painful, disabling spasms in Friedreich’s ataxia
.
Mov Disord
.
2005
Jun
;
20
(
6
):
758
9
.
[PubMed]
0885-3185
15.
Berntsson
SG
,
Holtz
A
,
Melberg
A
.
Does intrathecal baclofen have a place in the treatment of painful spasms in friedreich ataxia?
Case Rep Neurol
.
2013
Nov
;
5
(
3
):
201
3
.
[PubMed]
1662-680X
16.
Kalyvas
AV
,
Drosos
E
,
Korfias
S
,
Gatzonis
S
,
Themistocleous
M
,
Sakas
DE
.
Intrathecal Baclofen Therapy for Painful Muscle Spasms in a Patient with Friedreich’s Ataxia
.
Stereotact Funct Neurosurg
.
2018
;
96
(
2
):
127
30
.
[PubMed]
1011-6125
17.
Ramnarayan
R
,
Herculus
S
.
Intrathecal baclofen pump in spinocerebellar degeneration
.
Neurol India
.
2016
Nov-Dec
;
64
(
6
):
1354
5
.
[PubMed]
0028-3886
18.
Rosti-Otajärvi
E
,
Hämäläinen
P
,
Wiksten
A
,
Hakkarainen
T
,
Ruutiainen
J
.
Validity and reliability of the Fatigue Severity Scale in Finnish multiple sclerosis patients
.
Brain Behav
.
2017
Jun
;
7
(
7
):
e00743
.
[PubMed]
2162-3279
19.
Osborne
TL
,
Raichle
KA
,
Jensen
MP
,
Ehde
DM
,
Kraft
G
.
The reliability and validity of pain interference measures in persons with multiple sclerosis
.
J Pain Symptom Manage
.
2006
Sep
;
32
(
3
):
217
29
.
[PubMed]
0885-3924
20.
Raichle
KA
,
Osborne
TL
,
Jensen
MP
,
Cardenas
D
:
The reliability and validity of pain interference measures in persons with spinal cord injury.
The journal of pain : official journal of the American Pain Society
2006
;7:179-186.
21.
Tyler
EJ
,
Jensen
MP
,
Engel
JM
,
Schwartz
L
.
The reliability and validity of pain interference measures in persons with cerebral palsy
.
Arch Phys Med Rehabil
.
2002
Feb
;
83
(
2
):
236
9
.
[PubMed]
0003-9993
22.
Ehde
DM
,
Nitsch
KP
,
Smiley
JP
.
Measurement characteristics and clinical utility of the Brief Pain Inventory-Short Form for individuals with multiple sclerosis
.
Rehabil Psychol
.
2015
Nov
;
60
(
4
):
365
6
.
[PubMed]
0090-5550
23.
Tan
G
,
Jensen
MP
,
Thornby
JI
,
Shanti
BF
:
Validation of the Brief Pain Inventory for chronic nonmalignant pain.
The journal of pain : official journal of the American Pain Society
2004
;5:133-137.
24.
Post
MW
,
van Leeuwen
CM
,
van Koppenhagen
CF
,
de Groot
S
.
Validity of the Life Satisfaction questions, the Life Satisfaction Questionnaire, and the Satisfaction With Life Scale in persons with spinal cord injury
.
Arch Phys Med Rehabil
.
2012
Oct
;
93
(
10
):
1832
7
.
[PubMed]
0003-9993
25.
Wilson
JR
,
Hashimoto
RE
,
Dettori
JR
,
Fehlings
MG
.
Spinal cord injury and quality of life: a systematic review of outcome measures
.
Evid Based Spine Care J
.
2011
Feb
;
2
(
1
):
37
44
.
[PubMed]
1663-7976
26.
Bohannon
RW
,
Smith
MB
.
Interrater reliability of a modified Ashworth scale of muscle spasticity
.
Phys Ther
.
1987
Feb
;
67
(
2
):
206
7
.
[PubMed]
0031-9023
27.
Hsieh
JT
,
Wolfe
DL
,
Miller
WC
,
Curt
A
,
Team
SR
;
SCIRE Research Team
.
Spasticity outcome measures in spinal cord injury: psychometric properties and clinical utility
.
Spinal Cord
.
2008
Feb
;
46
(
2
):
86
95
.
[PubMed]
1362-4393
28.
Priebe
MM
,
Sherwood
AM
,
Thornby
JI
,
Kharas
NF
,
Markowski
J
.
Clinical assessment of spasticity in spinal cord injury: a multidimensional problem
.
Arch Phys Med Rehabil
.
1996
Jul
;
77
(
7
):
713
6
.
[PubMed]
0003-9993
29.
Moryl
N
,
Dave
V
,
Glare
P
,
Bokhari
A
,
Malhotra
VT
,
Gulati
A
,
Hung
J
,
Puttanniah
V
,
Griffo
Y
,
Tickoo
R
,
Wiesenthal
A
,
Horn
SD
,
Inturrisi
CE
:
Patient-Reported Outcomes and Opioid Use by Outpatient Cancer Patients.
The journal of pain : official journal of the American Pain Society
2017
30.
Baunsgaard
CB
,
Nissen
UV
,
Christensen
KB
,
Biering-Sørensen
F
.
Modified Ashworth scale and spasm frequency score in spinal cord injury: reliability and correlation
.
Spinal Cord
.
2016
Sep
;
54
(
9
):
702
8
.
[PubMed]
1362-4393
31.
Haas
J
.
Pathophysiology, assessment and management of multiple sclerosis spasticity: an update
.
Expert Rev Neurother
.
2011
Apr
;
11
(
4
Suppl
):
3
8
.
[PubMed]
1473-7175
32.
Friedman
JH
,
Amick
MM
.
Fatigue and daytime somnolence in Machado Joseph Disease (spinocerebellar ataxia type 3)
.
Mov Disord
.
2008
Jul
;
23
(
9
):
1323
4
.
[PubMed]
0885-3185
33.
Fu
R
,
Cui
SS
,
Du
JJ
,
Huang
P
,
He
YC
,
Gao
C
, et al
Validation of the Parkinson Fatigue Scale in Chinese Parkinson’s disease patients
.
Brain Behav
.
2017
May
;
7
(
6
):
e00712
.
[PubMed]
2162-3279
34.
Brands
I
,
Bol
Y
,
Stapert
S
,
Kohler
S
,
van Heugten
C
.
Is the effect of coping styles disease specific? Relationships with emotional distress and quality of life in acquired brain injury and multiple sclerosis
.
Clin Rehabil
.
2017
;
•••
:
269215517718367
.
[PubMed]
0269-2155
35.
Buhse
M
: The Elderly Person With Multiple Sclerosis: Clinical Implications for the Increasing Life-Span. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
2015
;47:333-339; quiz E331.
36.
Mathur
SN
,
Chu
SK
,
McCormick
Z
,
Chang Chien
GC
,
Marciniak
CM
: Long-term intrathecal baclofen: outcomes after more than 10 years of treatment. PM & R : the journal of injury, function, and rehabilitation
2014
;6:506-513 e501.
37.
Natale
M
,
D’Oria
S
,
Nero
VV
,
Squillante
E
,
Gentile
M
,
Rotondo
M
.
Long-term effects of intrathecal baclofen in multiple sclerosis
.
Clin Neurol Neurosurg
.
2016
Apr
;
143
:
121
5
.
[PubMed]
0303-8467
38.
Berntsson
SG
,
Landtblom
AM
,
Flensner
G
.
Cerebellar ataxia and intrathecal baclofen therapy: focus on patients´ experiences
.
PLoS One
.
2017
Jun
;
12
(
6
):
e0180054
.
[PubMed]
1932-6203
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.